Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report

CytomX Therapeutics, Inc.‘s CTMX share price was up 94.46% at last check on Monday.The stock surged after the company reported interim Phase 1 data for its EpCAM PROBODY ADC candidate, CX-2051, in advanced, late-line colorectal cancer (CRC).As of April 7, 25 advanced metastatic CRC patients were treated with CX-2051 across dose levels 1 through 5.CX-2051 was administered on a once every three-week schedule (Q3W).The 2.4 mg/kg and 4.8 mg/kg doses were single-patient dose escalation cohorts that were not anti ...